EXETER, N.H.--(BUSINESS WIRE)--
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology
company focused on the development and commercialization of its
proprietary Hi-VNI® Technology products that are used to
treat patients of all ages suffering from respiratory distress,
announced the pricing of its initial public offering of 4,000,000 shares
of common stock at a price to the public of $14.00 per share. In
addition, Vapotherm has granted the underwriters a 30-day option to
purchase up to an additional 600,000 shares of common stock, at the
initial public offering price less underwriting discounts and
commissions. The shares are expected to begin trading on the New York
Stock Exchange (“NYSE”) under the ticker symbol “VAPO” on November 14,
2018.
BofA Merrill Lynch and William Blair are acting as joint book-running
managers. Canaccord Genuity LLC is acting as lead manager, and BTIG, LLC
is acting as co-manager.
A registration statement relating to the securities being sold in this
offering was declared effective by the Securities and Exchange
Commission on November 13, 2018. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall there
be any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
The offering is being made only by means of a prospectus. When
available, a copy of the final prospectus may be obtained from BofA
Merrill Lynch, Attention: BofA Merrill Lynch, NC1-004-03-43, 200 North
College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus
Department, or email at dg.prospectus_requests@baml.com,
or from William Blair & Company, L.L.C., Attention: Prospectus
Department, 150 North Riverside Plaza, Chicago, IL 60606; via telephone
at (800) 621-0687 or via email at prospectus@williamblair.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181113006285/en/
Investor Contacts:
Mark Klausner or Mike Vallie
Westwicke
Partners
ir@vtherm.com
+1-855-255-7410
Source: Vapotherm, Inc.